** Shares of Mineralys Therapeutics MLYS.O down 0.5% at $14.89 early Tues as co looks to raise equity after its stock soared in previous session
** MLYS shares on Mon hit two-year high, before ending session up 42% at $14.96, after its blood pressure drug, lorundrostat, met main goals in mid- and late-stage trials
** After the bell, co commenced $250 mln stock offering to fund development of lorundrostat, as well as working capital, general purposes
** BofA, Evercore, Goldman Sachs, Stifel and Wells Fargo are jt bookrunners
** The Radnor, Pennsylvania-based firm has ~49.8 mln shares outstanding for ~$745 mln market cap
** All 7 analysts covering MLYS are bullish with $33 median PT, LSEG data shows
** Co went public in Feb 2023 IPO priced at $16
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
(( lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。